Human medicinehttps://www.ema.europa.eu/en/homepageHuman medicineen-gbCopyright: (C) European Medicines AgencyWed, 03 Jul 2024 15:24:44 +0200Thu, 11 Apr 2024 16:21:00 +0200Opinion/decision on a Paediatric investigation plan (PIP): Bosulif, Bosutinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0336/2023https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000727-pip01-09-m07Opinion/decision on a Paediatric investigation plan (PIP): Bosulif, Bosutinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Oncology, PIP number: P/0336/2023https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-000727-pip01-09-m07Thu, 11 Apr 2024 16:21:00 +0200Human medicineHuman medicines European public assessment report (EPAR): Bosulif, bosutinib, Date of authorisation: 27/03/2013, Revision: 25, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/bosulifHuman medicines European public assessment report (EPAR): Bosulif, bosutinib, Date of authorisation: 27/03/2013, Revision: 25, Status: Authorisedhttps://www.ema.europa.eu/en/medicines/human/EPAR/bosulifFri, 15 Mar 2024 16:45:00 +0100Human medicineBosulif-H-C-PSUSA-00010073-201503 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisationhttps://www.ema.europa.eu/system/files/documents/scientific-conclusion/wc500199605_en.pdfBosulif-H-C-PSUSA-00010073-201503 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisationhttps://www.ema.europa.eu/system/files/documents/scientific-conclusion/wc500199605_en.pdfFri, 08 Jan 2016 01:00:00 +0100Human medicine